https://news.medxy.ai/zh/post-stroke-arm-assessment/Medxy AIzh2026-11-13T04:01:03-08:00卒中后上肢评估新进展：FULMA单摄像头无标记动作捕捉系统 https://news.medxy.ai/ja/stroke-assessment-fulma/Medxy AIja2026-11-13T04:00:47-08:00脳卒中後上肢評価を前進させる：単一カメラ・マーカーレス動作解析システムFULMA https://news.medxy.ai/vi/upper-limb-stroke-assessment/Medxy AIvi2026-11-13T04:00:29-08:00Đánh giá chi trên sau đột quỵ tiến một bước: hệ thống chụp bắt chuyển động không gắn mốc dùng một camera FULMA https://news.medxy.ai/advancing-post-stroke-upper-limb-assessment-the-fulma-single-camera-markerless-motion-capture-system/Medxy AIen2026-11-13T04:00:13-08:00Advancing Post-Stroke Upper Limb Assessment: The FULMA Single-Camera Markerless Motion Capture System https://news.medxy.ai/zh/troponin-pathway-reassessment/Medxy AIzh2026-11-13T03:59:19-08:000/1 小时心肌肌钙蛋白路径再评估：安全性获证实，但急诊停留时间并未缩短 https://news.medxy.ai/ja/troponin-algorithm-evaluation/Medxy AIja2026-11-13T03:59:04-08:000/1時間心筋トロポニン・アルゴリズムの評価：安全性は確認されたが救急外来滞在時間は短縮せず https://news.medxy.ai/vi/troponin-0-1-hour-protocol-review/Medxy AIvi2026-11-13T03:58:47-08:00Đánh giá quy trình troponin tim 0/1 giờ: Xác nhận an toàn nhưng không rút ngắn thời gian lưu tại khoa cấp cứu https://news.medxy.ai/evaluating-the-0-1-hour-cardiac-troponin-pathway-safety-confirmed-but-no-reduction-in-emergency-department-stay/Medxy AIen2026-11-13T03:58:33-08:00Evaluating the 0/1-Hour Cardiac Troponin Pathway: Safety Confirmed but No Reduction in Emergency Department Stay https://news.medxy.ai/zh/adolescent-sti-screening/Medxy AIzh2026-11-13T03:57:52-08:00提升青少年性传播感染筛查：一项覆盖多院区的沙眼衣原体和淋病奈瑟菌初级保健质量改进计划 https://news.medxy.ai/ja/improving-adolescent-sti-screening-2/Medxy AIja2026-11-13T03:57:37-08:00若年層における性感染症スクリーニングの向上：複数施設を対象とした、クラミジア・トラコマティスおよび淋菌に関するプライマリ・ケアの質改善プログラム https://news.medxy.ai/vi/improving-adolescent-sti-screening/Medxy AIvi2026-11-13T03:57:20-08:00Nâng cao sàng lọc STI ở thanh thiếu niên: Sáng kiến cải tiến chất lượng đa cơ sở trong chăm sóc ban đầu đối với Chlamydia và Gonorrhea https://news.medxy.ai/enhancing-adolescent-sti-screening-a-multisite-primary-care-quality-improvement-initiative-for-chlamydia-and-gonorrhea/Medxy AIen2026-11-13T03:57:05-08:00Enhancing Adolescent STI Screening: A Multisite Primary Care Quality Improvement Initiative for Chlamydia and Gonorrhea https://news.medxy.ai/zh/bone-quality-differences/Medxy AIzh2026-11-13T03:56:31-08:00类风湿关节炎与银屑病关节炎的骨质量差异：7年纵向HR-pQCT研究 https://news.medxy.ai/ja/bone-quality-differences-2/Medxy AIja2026-11-13T03:56:13-08:00関節リウマチと乾癬性関節炎で骨質への影響はどう異なるか：7年間のHR-pQCT縦断研究 https://news.medxy.ai/vi/disease-activity-bone-quality/Medxy AIvi2026-11-13T03:55:55-08:00Ảnh hưởng khác biệt của hoạt tính bệnh lên chất lượng xương ở viêm khớp dạng thấp và viêm khớp vảy nến: nghiên cứu HR-pQCT theo dõi dọc 7 năm https://news.medxy.ai/differential-impact-of-disease-activity-on-bone-quality-in-rheumatoid-and-psoriatic-arthritis-a-7-year-longitudinal-hr-pqct-study/Medxy AIen2026-11-13T03:55:39-08:00Differential Impact of Disease Activity on Bone Quality in Rheumatoid and Psoriatic Arthritis: A 7-Year Longitudinal HR-pQCT Study https://news.medxy.ai/zh/us-lung-transplant-data-disparities/Medxy AIzh2026-11-13T03:55:01-08:00美国肺移植候选者临床数据更新差异：对分配公平性的启示 https://news.medxy.ai/ja/intercenter-variation-in-lung-transplant-candidates/Medxy AIja2026-11-13T03:54:47-08:00米国肺移植候補者の臨床データ更新にみられるセンター間差と割り当て公平性への示唆 https://news.medxy.ai/vi/us-lung-transplant-data-disparities-2/Medxy AIvi2026-11-13T03:54:29-08:00Sự khác biệt trong việc cập nhật dữ liệu lâm sàng cho các ứng viên chờ ghép phổi tại Hoa Kỳ: Những hệ quả đối với sự công bằng trong phân bổ https://news.medxy.ai/assessing-center-level-variability-in-clinical-data-updates-for-us-lung-transplant-candidates-implications-for-allocation-equity/Medxy AIen2026-11-13T03:54:15-08:00Assessing Center-Level Variability in Clinical Data Updates for US Lung Transplant Candidates: Implications for Allocation Equity https://news.medxy.ai/zh/biologic-treatment-optimization/Medxy AIzh2026-11-13T03:53:39-08:00借助剂末效应优化化脓性汗腺炎生物制剂治疗：改善患者结局的新思路 https://news.medxy.ai/ja/optimizing-hidradenitis-suppurativa-treatment/Medxy AIja2026-11-13T03:53:21-08:00化膿性汗腺炎の生物学的製剤治療を最適化する：投与末期効果を活用して患者アウトカムを改善する https://news.medxy.ai/vi/biologic-treatment-optimization-2/Medxy AIvi2026-11-13T03:53:02-08:00Tối ưu hóa điều trị sinh học trong viêm tuyến mồ hôi mủ: Khai thác hiện tượng cuối liều để cải thiện kết cục cho bệnh nhân https://news.medxy.ai/optimizing-biologic-therapy-for-hidradenitis-suppurativa-harnessing-the-end-of-dose-effect-to-improve-patient-outcomes/Medxy AIen2026-11-13T03:52:47-08:00Optimizing Biologic Therapy for Hidradenitis Suppurativa: Harnessing the End-of-Dose Effect to Improve Patient Outcomes https://news.medxy.ai/zh/preoperative-endovascular-limb-salvage/Medxy AIzh2026-11-13T03:52:09-08:00术前经皮血管内介入如何助力下肢重建保肢 https://news.medxy.ai/ja/optimizing-limb-salvage/Medxy AIja2026-11-13T03:51:55-08:00下肢再建の肢温存を最適化するには：free tissue transferにおける術前経皮的血管内治療の役割 https://news.medxy.ai/vi/limb-salvage-optimization/Medxy AIvi2026-11-13T03:51:36-08:00Tối ưu hóa cứu chi: Vai trò của can thiệp nội mạch qua da trước phẫu thuật trong chuyển vạt mô tự do để tái tạo chi dưới https://news.medxy.ai/optimizing-limb-salvage-the-role-of-preoperative-percutaneous-endovascular-intervention-in-free-tissue-transfer-for-lower-extremity-reconstruction/Medxy AIen2026-11-13T03:51:22-08:00Optimizing Limb Salvage: The Role of Preoperative Percutaneous Endovascular Intervention in Free Tissue Transfer for Lower-Extremity Reconstruction https://news.medxy.ai/zh/family-satisfaction-icu-assessment-2/Medxy AIzh2026-11-13T03:50:40-08:00优化成人ICU的家属满意度评估：12项版FS-ICUshort量表的开发与验证 https://news.medxy.ai/ja/family-satisfaction-icu-assessment/Medxy AIja2026-11-13T03:50:23-08:00成人ICUにおける家族満足度評価を最適化する：12項目版FS-ICUshort調査の開発と検証 https://news.medxy.ai/vi/family-satisfaction-survey/Medxy AIvi2026-11-13T03:50:02-08:00Tối ưu hóa đo lường mức độ hài lòng của gia đình tại ICU người lớn: Phát triển và thẩm định bảng khảo sát FS-ICUshort 12 mục https://news.medxy.ai/optimizing-family-satisfaction-measurement-in-adult-icus-development-and-validation-of-the-12-item-fs-icushort-survey/Medxy AIen2026-11-13T03:49:45-08:00Optimizing Family Satisfaction Measurement in Adult ICUs: Development and Validation of the 12-Item FS-ICUshort Survey https://news.medxy.ai/zh/wearables-frailty-assessment-fairness/Medxy AIzh2026-11-13T03:49:00-08:00可穿戴技术与医院衰弱风险评分的融合：破解偏倚，推动衰弱评估公平化 https://news.medxy.ai/ja/wearable-frailty-assessment/Medxy AIja2026-11-13T03:48:46-08:00ウェアラブル技術とHospital Frailty Risk Scoreを統合する：フレイル評価におけるバイアス是正と公平性の推進 https://news.medxy.ai/vi/wearable-frailty-assessment-2/Medxy AIvi2026-11-13T03:48:27-08:00Tích hợp công nghệ thiết bị đeo với Hospital Frailty Risk Score: Giảm thiên lệch và thúc đẩy công bằng trong đánh giá yếu ớt https://news.medxy.ai/integrating-wearable-technology-with-hospital-frailty-risk-score-addressing-bias-and-promoting-equity-in-frailty-assessment/Medxy AIen2026-11-13T03:48:12-08:00Integrating Wearable Technology with Hospital Frailty Risk Score: Addressing Bias and Promoting Equity in Frailty Assessment https://news.medxy.ai/zh/cd20-car-t-waldenstrom-macroglobulinemia/Medxy AIzh2026-11-13T03:47:33-08:00CD20 靶向自体 CAR T 细胞治疗为难治性 Waldenström 巨球蛋白血症带来新希望 https://news.medxy.ai/ja/cd20-car-t-therapy-2/Medxy AIja2026-11-13T03:47:16-08:00BTKi不応性Waldenström macroglobulinemiaに挑むCD20標的自己CAR-T細胞療法 https://news.medxy.ai/vi/cd20-car-t-cell-therapy/Medxy AIvi2026-11-13T03:47:00-08:00Liệu pháp CAR T tự thân nhắm đích CD20: hướng điều trị mới đầy triển vọng cho Waldenström macroglobulinemia kháng trị https://news.medxy.ai/cd20-car-t-therapy/Medxy AIen2026-11-13T03:46:45-08:00Innovative CD20-Directed Autologous CAR T-Cell Therapy for Treatment-Refractory Waldenström Macroglobulinemia https://news.medxy.ai/patient-versus-surrogate-decision-making-for-life-sustaining-treatment-and-terminal-care-intensity/Medxy AIen2026-11-13T03:45:30-08:00Patient versus Surrogate Decision-Making for Life-Sustaining Treatment and Terminal Care Intensity https://news.medxy.ai/zh/electronic-behavioral-nudges-preoperative-testing-2/Medxy AIzh2026-11-13T03:44:53-08:00电子化行为干预能否减少低价值的术前检查：来自一项实用性随机临床试验的启示 https://news.medxy.ai/ja/can-digital-interventions-reduce-preoperative-testing/Medxy AIja2026-11-13T03:44:28-08:00電子的行動介入は低価値の術前検査を減らせるか：実用的ランダム化臨床試験からの示唆 https://news.medxy.ai/vi/electronic-behavioral-nudges-preoperative-testing/Medxy AIvi2026-11-13T03:44:02-08:00Tác động của các “nudges” hành vi điện tử lên xét nghiệm tiền phẫu giá trị thấp: Nhận định từ một thử nghiệm lâm sàng ngẫu nhiên thực dụng https://news.medxy.ai/effect-of-electronic-behavioral-nudges-on-low-value-preoperative-testing-insights-from-a-pragmatic-randomized-clinical-trial/Medxy AIen2026-11-13T03:43:41-08:00Effect of Electronic Behavioral Nudges on Low-Value Preoperative Testing: Insights from a Pragmatic Randomized Clinical Trial https://news.medxy.ai/zh/throat-cancer-microbes/Medxy AIzh2026-11-13T03:42:53-08:00喉癌微生物特征揭秘：聚焦 Parvimonas 与 Campylobacter 的新型治疗潜力 https://news.medxy.ai/ja/laryngeal-cancer-microbiome/Medxy AIja2026-11-13T03:42:34-08:00喉頭がんの微生物シグネチャーを解き明かす：Parvimonas と Campylobacter を標的とした新規治療の可能性 https://news.medxy.ai/vi/microbes-laryngeal-cancer/Medxy AIvi2026-11-13T03:42:16-08:00Giải mã dấu ấn vi sinh vật trong ung thư thanh quản: Parvimonas và Campylobacter như đích điều trị mới https://news.medxy.ai/unveiling-microbial-signatures-in-laryngeal-cancer-targeting-parvimonas-and-campylobacter-for-novel-therapeutics/Medxy AIen2026-11-13T03:42:01-08:00Unveiling Microbial Signatures in Laryngeal Cancer: Targeting Parvimonas and Campylobacter for Novel Therapeutics https://news.medxy.ai/zh/liver-transplantation-combined-cancer/Medxy AIzh2026-11-13T03:41:13-08:00重新审视合并性肝细胞-胆管癌的肝移植：精选患者的疗效可与肝细胞癌相媲美 https://news.medxy.ai/ja/rethinking-liver-transplantation/Medxy AIja2026-11-13T03:40:54-08:00複合型肝細胞・胆管癌に対する肝移植を再考する：選択症例では肝細胞癌に匹敵する成績 https://news.medxy.ai/vi/liver-transplantation-combined-cancer-2/Medxy AIvi2026-11-13T03:40:30-08:00Đánh giá lại ghép gan cho ung thư biểu mô tế bào gan–ung thư đường mật phối hợp: kết cục tương đương ung thư biểu mô tế bào gan ở nhóm bệnh nhân được chọn lọc https://news.medxy.ai/reevaluating-liver-transplantation-for-combined-hepatocellular-cholangiocarcinoma-comparable-outcomes-to-hepatocellular-carcinoma-in-selected-patients/Medxy AIen2026-11-13T03:40:12-08:00Reevaluating Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma: Comparable Outcomes to Hepatocellular Carcinoma in Selected Patients https://news.medxy.ai/zh/urge-incontinence-phenotypes/Medxy AIzh2026-11-13T03:39:19-08:00急迫性尿失禁的生理分型：基于聚类分析识别三种不同表型 https://news.medxy.ai/ja/understanding-urge-incontinence/Medxy AIja2026-11-13T03:38:56-08:00切迫性尿失禁を読み解く：クラスター解析で見えた異なる生理学的表現型 https://news.medxy.ai/vi/urgent-urinary-incontinence-phenotypes/Medxy AIvi2026-11-13T03:38:36-08:00Giải mã tiểu không tự chủ cấp bách: Nhận diện các kiểu hình sinh lý khác nhau bằng phân tích cụm https://news.medxy.ai/decoding-urgency-urinary-incontinence-identifying-distinct-physiological-phenotypes-via-cluster-analysis/Medxy AIen2026-11-13T03:38:20-08:00Decoding Urgency Urinary Incontinence: Identifying Distinct Physiological Phenotypes via Cluster Analysis https://news.medxy.ai/zh/elafibranor-pbc-alp-normalization/Medxy AIzh2026-11-13T03:37:38-08:00Elafibranor助力原发性胆汁性胆管炎ALP正常化：来自III期ELSPIRE试验及相关研究的综合证据 https://news.medxy.ai/ja/elafibranor-pbc-treatment/Medxy AIja2026-11-13T03:37:19-08:00UDCA不十分反応の原発性胆汁性胆管炎に対する第二選択治療としてのElafibranor――第III相ELSPIRE試験と関連研究からみたALP正常化の意義 https://news.medxy.ai/vi/elafibranor-pbc-alp-normalization-elspire/Medxy AIvi2026-11-13T03:36:58-08:00Elafibranor thúc đẩy quá trình bình thường hóa nồng độ ALP trong bệnh viêm đường mật nguyên phát: Bằng chứng toàn diện từ thử nghiệm giai đoạn III ELSPIRE và các nghiên cứu liên quan https://news.medxy.ai/elafibranor-as-an-effective-second-line-treatment-to-normalize-alkaline-phosphatase-in-primary-biliary-cholangitis-with-incomplete-response-to-ursodeoxycholic-acid/Medxy AIen2026-11-13T03:36:40-08:00Elafibranor as an Effective Second-Line Treatment to Normalize Alkaline Phosphatase in Primary Biliary Cholangitis with Incomplete Response to Ursodeoxycholic Acid: Synthesizing Evidence from the Phase III ELSPIRE Trial and Related Studies https://news.medxy.ai/zh/multiple-sclerosis-ris-revised-criteria/Medxy AIzh2026-11-13T03:35:51-08:00RIS中的多发性硬化能更早识别：2024年 McDonald 标准修订带来的新启示 https://news.medxy.ai/ja/early-ms-diagnosis-imaging-2/Medxy AIja2026-11-13T03:35:34-08:00RISにおける多発性硬化症のより早期の特定：2024年マクドナルド診断基準改訂がもたらす新たな示唆 https://news.medxy.ai/vi/early-ms-diagnosis-imaging/Medxy AIvi2026-11-13T03:35:13-08:00Chẩn đoán sớm xơ cứng rải rác ở hội chứng biệt lập trên hình ảnh: Những điểm mới từ bản sửa đổi tiêu chuẩn McDonald 2024 https://news.medxy.ai/early-diagnosis-of-multiple-sclerosis-in-radiologically-isolated-syndrome-insights-from-2024-mcdonald-criteria-revisions/Medxy AIen2026-11-13T03:34:56-08:00Early Diagnosis of Multiple Sclerosis in Radiologically Isolated Syndrome: Insights from 2024 McDonald Criteria Revisions https://news.medxy.ai/zh/vitamin-d-scoliosis-bone-health/Medxy AIzh2026-11-13T03:34:11-08:00维生素D缺乏对青少年特发性脊柱侧弯骨健康的影响：一项6年前瞻性研究的启示 https://news.medxy.ai/ja/vitamin-d-scoliosis-bone-health-3/Medxy AIja2026-11-13T03:33:48-08:00思春期特発性脊柱側弯症におけるビタミンD欠乏と骨健康への影響：6年間前向き研究からの知見 https://news.medxy.ai/vi/vitamin-d-scoliosis-bone-health-2/Medxy AIvi2026-11-13T03:33:28-08:00Ảnh hưởng của thiếu hụt vitamin D lên sức khỏe xương trong vẹo cột sống vô căn ở tuổi vị thành niên: Những phát hiện từ nghiên cứu tiến cứu 6 năm https://news.medxy.ai/impact-of-vitamin-d-deficiency-on-bone-health-in-adolescent-idiopathic-scoliosis-insights-from-a-6-year-prospective-study/Medxy AIen2026-11-13T03:33:11-08:00Impact of Vitamin D Deficiency on Bone Health in Adolescent Idiopathic Scoliosis: Insights from a 6-Year Prospective Study https://news.medxy.ai/zh/biomarker-based-takotsubo-score/Medxy AIzh2026-11-13T03:32:30-08:00基于生物标志物识别Takotsubo综合征：BioTAK评分的开发与验证 https://news.medxy.ai/ja/detecting-takotsubo-syndrome/Medxy AIja2026-11-13T03:32:08-08:00冠動脈造影前にたこつぼ症候群を見分ける――BioTAKスコアの開発と検証 https://news.medxy.ai/vi/biotak-takotsubo-diagnosis/Medxy AIvi2026-11-13T03:31:45-08:00BioTAK: Bước tiến chẩn đoán hội chứng Takotsubo dựa trên biomarker https://news.medxy.ai/biomarker-based-diagnosis-of-takotsubo-syndrome-development-and-validation-of-the-biotak-score/Medxy AIen2026-11-13T03:31:24-08:00Biomarker-Based Diagnosis of Takotsubo Syndrome: Development and Validation of the BioTAK Score https://news.medxy.ai/zh/poorly-differentiated-thyroid-cancer-staging/Medxy AIzh2026-11-13T03:30:12-08:00分化不良甲状腺癌TNM分期全球方案：预后分层的新范式 https://news.medxy.ai/ja/international-tnm-staging-proposal/Medxy AIja2026-11-13T03:29:50-08:00低分化甲状腺癌のTNM病期分類に向けた国際提案：予後層別化を変える新たな枠組み https://news.medxy.ai/vi/global-tnm-staging-thyroid-cancer/Medxy AIvi2026-11-13T03:29:31-08:00Đề xuất toàn cầu về hệ thống TNM cho ung thư tuyến giáp biệt hóa kém: Bước ngoặt trong phân tầng tiên lượng https://news.medxy.ai/global-proposal-for-the-tnm-staging-system-for-poorly-differentiated-thyroid-cancer-a-paradigm-shift-in-prognostic-stratification/Medxy AIen2026-11-13T03:29:05-08:00Global Proposal for the TNM Staging System for Poorly Differentiated Thyroid Cancer: A Paradigm Shift in Prognostic Stratification https://news.medxy.ai/zh/acetabular-rim-microfracture/Medxy AIzh2026-11-13T03:28:15-08:00髋臼缘微骨折如何增强髋关节盂唇重建：来自猪模型的研究启示 https://news.medxy.ai/ja/enhancing-labral-reconstruction/Medxy AIja2026-11-13T03:27:58-08:00寛骨臼縁マイクロフラクチャーで股関節唇再建を強化する：ブタモデルからの知見 https://news.medxy.ai/vi/acetabular-rim-microfracture-enhancing-labral-reconstruction/Medxy AIvi2026-11-13T03:27:36-08:00Tăng cường tái tạo sụn viền khớp háng bằng kỹ thuật vi gãy xương viền ổ cối: Những hiểu biết từ mô hình lợn https://news.medxy.ai/enhancing-hip-labral-reconstruction-with-acetabular-rim-microfracture-insights-from-a-porcine-model/Medxy AIen2026-11-13T03:27:21-08:00Enhancing Hip Labral Reconstruction with Acetabular Rim Microfracture: Insights from a Porcine Model https://news.medxy.ai/zh/malnutrition-amputation-outcomes/Medxy AIzh2026-11-13T03:26:42-08:00营养不良如何影响缺血性血管疾病所致大下肢截肢后的结局：一项纵向研究的启示 https://news.medxy.ai/ja/malnutrition-amputation-outcomes-3/Medxy AIja2026-11-13T03:26:23-08:00血行障害性大切断後の低栄養が転帰に及ぼす影響：縦断研究からみた知見 https://news.medxy.ai/vi/malnutrition-amputation-outcomes-2/Medxy AIvi2026-11-13T03:26:05-08:00Tác động của suy dinh dưỡng đến kết cục sau cắt cụt chi dưới lớn do bệnh lý mạch máu: Những phát hiện từ một nghiên cứu theo dõi dọc https://news.medxy.ai/impact-of-undernutrition-on-outcomes-after-dysvascular-major-lower-limb-amputation-insights-from-a-longitudinal-study/Medxy AIen2026-11-13T03:25:49-08:00Impact of Undernutrition on Outcomes After Dysvascular Major Lower Limb Amputation: Insights from a Longitudinal Study https://news.medxy.ai/zh/individualized-osteoradionecrosis-risk/Medxy AIzh2026-11-13T03:25:09-08:00放疗前拔牙对头颈癌骨放射性坏死风险的个体化影响：来自因果机器学习的证据 https://news.medxy.ai/ja/individualized-osteoradionecrosis-risk-machine-learning/Medxy AIja2026-11-13T03:24:50-08:00頭頸部がんにおける放射線治療前の抜歯が骨放射線壊死リスクに及ぼす個別の影響：因果機械学習によるエビデンス https://news.medxy.ai/vi/tooth-extraction-radiation-risk/Medxy AIvi2026-11-13T03:24:26-08:00Nhổ răng trước xạ trị ở bệnh ung thư đầu cổ: tác động cá thể hóa lên nguy cơ hoại tử xương do tia xạ https://news.medxy.ai/personalized-impact-of-pre-radiotherapy-tooth-extraction-on-osteoradionecrosis-risk-in-head-and-neck-cancer-insights-from-causal-machine-learning/Medxy AIen2026-11-13T03:24:09-08:00Personalized Impact of Pre-Radiotherapy Tooth Extraction on Osteoradionecrosis Risk in Head and Neck Cancer: Insights from Causal Machine Learning https://news.medxy.ai/zh/ct-coronary-angiography/Medxy AIzh2026-11-13T03:23:26-08:00急性胸痛排除心肌梗死后：门诊CT冠状动脉造影是否真的有用？ https://news.medxy.ai/ja/outpatient-ct-coronary-angiography/Medxy AIja2026-11-13T03:23:08-08:00急性胸痛に対する外来CT冠動脈造影の意義：心筋梗塞除外後の検証 https://news.medxy.ai/evaluating-outpatient-ct-coronary-angiography-in-acute-chest-pain-post-myocardial-infarction-rule-out/Medxy AIen2026-11-13T03:22:31-08:00Evaluating Outpatient CT Coronary Angiography in Acute Chest Pain Post-Myocardial Infarction Rule-Out https://news.medxy.ai/nurse-practitioner-led-pathway-slashes-specialist-wait-times-by-75-for-high-risk-liver-disease-patients/Medxy AIen2026-11-12T14:26:26-08:00Nurse Practitioner-Led Pathway Slashes Specialist Wait Times by 75% for High-Risk Liver Disease Patients https://news.medxy.ai/zh/parkinsons-pain-perception/Medxy AIzh2026-11-12T02:46:09-08:00帕金森病疼痛感知：基于患者叙述改进照护的启示 https://news.medxy.ai/ja/parkinsons-pain-perception-perspectives/Medxy AIja2026-11-12T02:45:49-08:00パーキンソン病における疼痛の捉え方：患者の語りに基づくケア改善への示唆 https://news.medxy.ai/vi/parkinsons-pain-perspectives/Medxy AIvi2026-11-12T02:45:30-08:00Đau trong bệnh Parkinson được nhìn nhận như thế nào? Góc nhìn từ lời kể của người bệnh để cải thiện chăm sóc https://news.medxy.ai/pain-perception-in-parkinsons-disease-insights-from-patient-narratives-to-improve-care/Medxy AIen2026-11-12T02:45:14-08:00Pain Perception in Parkinson’s Disease: Insights from Patient Narratives to Improve Care https://news.medxy.ai/zh/aesthetic-crown-lengthening-trial/Medxy AIzh2026-11-12T02:44:33-08:00美学冠延长术中 piezosurgery 与旋转切骨钻的比较：一项裂口随机试验 https://news.medxy.ai/ja/piezosurgery-vs-rotary-burs/Medxy AIja2026-11-12T02:44:15-08:00審美的歯冠長延長術におけるPiezosurgeryとRotary Bursの比較：スプリットマウス無作為化試験 https://news.medxy.ai/vi/piezosurgery-vs-rotary-drill/Medxy AIvi2026-11-12T02:43:53-08:00Piezosurgery hay mũi khoan xoay: đâu là lựa chọn tốt hơn trong kéo dài thân răng thẩm mỹ? https://news.medxy.ai/comparing-piezosurgery-and-rotary-burs-in-aesthetic-crown-lengthening-a-split-mouth-randomised-trial/Medxy AIen2026-11-12T02:43:34-08:00Comparing Piezosurgery and Rotary Burs in Aesthetic Crown Lengthening: A Split-Mouth Randomised Trial https://news.medxy.ai/zh/ruzaltatug-egfr-lung-cancer/Medxy AIzh2026-11-12T02:42:55-08:00HER3 靶向药物 Ruzaltatug rezetecan 治疗 EGFR 突变晚期 NSCLC：HERON-Lung01 3 期中期分析优于化疗 https://news.medxy.ai/ja/ruzaltatug-rezetecan-vs-chemotherapy/Medxy AIja2026-11-12T02:42:35-08:00EGFR変異陽性進行NSCLCに対するRuzaltatug rezetecanと化学療法の比較：HERON-Lung01第3相中間解析 https://news.medxy.ai/vi/ruzaltatug-outperforms-chemotherapy/Medxy AIvi2026-11-12T02:42:09-08:00Ruzaltatug rezetecan vượt hóa trị ở NSCLC tiến triển có đột biến EGFR sau điều trị EGFR-TKI: Phân tích tạm thời pha 3 HERON-Lung01 https://news.medxy.ai/ruzaltatug-rezetecan-versus-chemotherapy-for-egfr-mutated-advanced-nsclc-post-egfr-tki-therapy-interim-phase-3-heron-lung01-analysis/Medxy AIen2026-11-12T02:41:50-08:00Ruzaltatug Rezetecan Versus Chemotherapy for EGFR-Mutated Advanced NSCLC Post-EGFR TKI Therapy: Interim Phase 3 HERON-Lung01 Analysis https://news.medxy.ai/ja/mild-pyuria-antibiotics-suspected-pediatric-uti/Medxy AIja2026-11-12T02:40:50-08:00小児のUTI疑いにおける軽度膿尿と抗菌薬処方 https://news.medxy.ai/vi/low-grade-pyuria-antibiotic-prescribing/Medxy AIvi2026-11-12T02:40:28-08:00Tiểu mủ mức độ thấp và việc kê đơn kháng sinh trong nghi ngờ nhiễm khuẩn đường tiết niệu ở trẻ em https://news.medxy.ai/low-level-pyuria-and-antibiotic-prescribing-for-suspected-urinary-tract-infection-in-children/Medxy AIen2026-11-12T02:40:11-08:00Low-Level Pyuria and Antibiotic Prescribing for Suspected Urinary Tract Infection in Children https://news.medxy.ai/zh/blinatumomab-vasculitis-study/Medxy AIzh2026-11-12T02:39:32-08:00Blinatumomab 治疗皮肌炎与难治性 ANCA 相关性血管炎的新探索：来自2例患者研究的启示 https://news.medxy.ai/ja/blinatumomab-treatment-study/Medxy AIja2026-11-12T02:39:15-08:00皮膚筋炎と難治性ANCA関連血管炎への新規治療としてのブリナツモマブ：2例研究から得られた知見 https://news.medxy.ai/vi/promising-treatment-for-dermatomyositis-and-anca-vasculitis/Medxy AIvi2026-11-12T02:38:57-08:00Blinatumomab: Hướng điều trị mới đầy hứa hẹn cho viêm da cơ và viêm mạch liên quan ANCA kháng trị từ nghiên cứu trên hai bệnh nhân https://news.medxy.ai/exploring-blinatumomab-as-a-novel-therapy-for-dermatomyositis-and-refractory-anca-associated-vasculitis-insights-from-a-two-patient-study/Medxy AIen2026-11-12T02:38:41-08:00Exploring Blinatumomab as a Novel Therapy for Dermatomyositis and Refractory ANCA-Associated Vasculitis: Insights from a Two-Patient Study https://news.medxy.ai/zh/living-donor-mental-health/Medxy AIzh2026-11-12T02:38:00-08:00提升活体捐献者心理健康结局：当前认识与未来方向 https://news.medxy.ai/ja/improving-donor-mental-health/Medxy AIja2026-11-12T02:37:36-08:00生体ドナーのメンタルヘルス転帰を高めるには：現状の知見と今後の展望 https://news.medxy.ai/vi/mental-health-outcomes/Medxy AIvi2026-11-12T02:37:03-08:00Nâng cao kết cục sức khỏe tâm thần ở người hiến sống: hiểu biết hiện nay và định hướng tương lai https://news.medxy.ai/enhancing-mental-health-outcomes-in-living-donors-current-insights-and-future-directions/Medxy AIen2026-11-12T02:36:45-08:00Enhancing Mental Health Outcomes in Living Donors: Current Insights and Future Directions https://news.medxy.ai/zh/ruxolitinib-atopic-dermatitis/Medxy AIzh2026-11-12T02:36:04-08:00Ruxolitinib cream治疗儿童特应性皮炎：来自3期TRuE-AD3试验的长期安全性与持续控制结果 https://news.medxy.ai/ja/ruxolitinib-long-term-safety/Medxy AIja2026-11-12T02:35:44-08:00小児アトピー性皮膚炎に対するルキソリチニブクリームの長期安全性と持続的コントロール：第3相TRuE-AD3試験からの知見 https://news.medxy.ai/vi/ruxolitinib-atopic-dermatitis-2/Medxy AIvi2026-11-12T02:35:21-08:00Kem ruxolitinib trong viêm da cơ địa ở trẻ em: bằng chứng về độ an toàn dài hạn và kiểm soát bệnh bền vững từ thử nghiệm pha 3 TRuE-AD3 https://news.medxy.ai/long-term-safety-and-sustained-control-of-atopic-dermatitis-in-children-treated-with-ruxolitinib-cream-insights-from-the-phase-3-true-ad3-trial/Medxy AIen2026-11-12T02:35:03-08:00Long-term Safety and Sustained Control of Atopic Dermatitis in Children Treated with Ruxolitinib Cream: Insights from the Phase 3 TRuE-AD3 Trial https://news.medxy.ai/zh/diep-flap-complications/Medxy AIzh2026-11-12T02:34:19-08:00DIEP皮瓣乳房重建如何减少供区并发症？腹直肌后可吸收聚乙交酯网片与个体化疝风险评估的新证据 https://news.medxy.ai/ja/diep-flap-complications-2/Medxy AIja2026-11-12T02:34:01-08:00DIEP flap乳房再建後のドナー部位合併症を減らすには：retrorectusポリグラクチンメッシュの有効性と個別化ヘルニアリスク推定 https://news.medxy.ai/vi/reducing-donor-site-complications/Medxy AIvi2026-11-12T02:33:08-08:00Giảm biến chứng tại vị trí cho vạt trong tái tạo vú bằng vạt DIEP: Hiệu quả của lưới polyglactin đặt retrorectus và ước tính nguy cơ thoát vị cá thể hóa https://news.medxy.ai/reducing-donor-site-complications-in-diep-flap-breast-reconstruction-the-efficacy-of-retrorectus-polyglactin-mesh-and-personalized-hernia-risk-estimation/Medxy AIen2026-11-12T02:32:49-08:00Reducing Donor-Site Complications in DIEP Flap Breast Reconstruction: The Efficacy of Retrorectus Polyglactin Mesh and Personalized Hernia Risk Estimation https://news.medxy.ai/zh/long-term-sepsis-mortality/Medxy AIzh2026-11-12T02:32:06-08:00脓毒症幸存者的长期死亡负担有多重？——来自加泰罗尼亚15年队列研究的启示 https://news.medxy.ai/ja/long-term-sepsis-mortality-3/Medxy AIja2026-11-12T02:31:45-08:00敗血症生存者における長期死亡負担を可視化：カタルーニャ15年間コホート研究からの知見 https://news.medxy.ai/vi/long-term-sepsis-mortality-2/Medxy AIvi2026-11-12T02:31:26-08:00Gánh nặng tử vong dài hạn ở người sống sót sau sepsis: phát hiện từ nghiên cứu đoàn hệ 15 năm tại Catalonia https://news.medxy.ai/unveiling-the-long-term-mortality-burden-among-sepsis-survivors-insights-from-a-15-year-catalonia-cohort-study/Medxy AIen2026-11-12T02:31:04-08:00Unveiling the Long-Term Mortality Burden Among Sepsis Survivors: Insights from a 15-Year Catalonia Cohort Study https://news.medxy.ai/ja/vr-pain-relief-feasibility/Medxy AIja2026-11-12T02:30:25-08:00鎌状赤血球症の疼痛緩和におけるVRの実現可能性と受容性：パイロット研究 https://news.medxy.ai/vi/virtual-reality-pain-relief/Medxy AIvi2026-11-12T02:30:09-08:00Thực tế ảo có khả thi trong giảm đau khi tắc nghẽn mạch ở bệnh hồng cầu hình liềm? Kết quả từ một nghiên cứu thí điểm https://news.medxy.ai/feasibility-and-acceptability-of-virtual-reality-for-pain-relief-during-vaso-occlusive-episodes-in-sickle-cell-disease-a-pilot-study/Medxy AIen2026-11-12T02:29:50-08:00Feasibility and Acceptability of Virtual Reality for Pain Relief During Vaso-occlusive Episodes in Sickle Cell Disease: A Pilot Study https://news.medxy.ai/zh/functional-platelet-rig-i/Medxy AIzh2026-11-12T02:29:11-08:00血小板中的功能性 RIG-I：流感感染期间血栓调控的新机制 https://news.medxy.ai/ja/functional-platelet-rig-i-2/Medxy AIja2026-11-12T02:28:51-08:00血小板における機能的RIG-I：インフルエンザ感染時の血栓形成を調節する新たな因子 https://news.medxy.ai/vi/rigi-platelet-function-thrombosis/Medxy AIvi2026-11-12T02:28:32-08:00RIG-I chức năng trong tiểu cầu: Bộ điều biến mới của huyết khối trong nhiễm cúm https://news.medxy.ai/functional-rig-i-in-platelets-a-novel-modulator-of-thrombosis-during-influenza-infection/Medxy AIen2026-11-12T02:28:14-08:00Functional RIG-I in Platelets: A Novel Modulator of Thrombosis During Influenza Infection https://news.medxy.ai/zh/predicting-copd-risk/Medxy AIzh2026-11-12T02:27:34-08:00预测 COPD 发生：跨多元队列验证实用 Pre-COPD 评分体系 https://news.medxy.ai/ja/predicting-copd-onset/Medxy AIja2026-11-12T02:27:16-08:00COPD発症を見据えた予測：実用的Pre-COPDスコアの多様コホートにおける検証 https://news.medxy.ai/vi/predicting-copd-onset-2/Medxy AIvi2026-11-12T02:26:57-08:00Dự báo khởi phát COPD: Thẩm định một thang điểm Pre-COPD thực tiễn trên nhiều đoàn hệ khác nhau https://news.medxy.ai/predicting-copd-onset-validation-of-a-practical-pre-copd-scoring-system-across-diverse-cohorts/Medxy AIen2026-11-12T02:26:40-08:00Predicting COPD Onset: Validation of a Practical Pre-COPD Scoring System Across Diverse Cohorts https://news.medxy.ai/zh/primary-congenital-glaucoma-treatment-comparison/Medxy AIzh2026-11-12T02:25:44-08:00原发性先天性青光眼中单纯小梁切开术与联合小梁切开术-小梁切除术的3年疗效比较 https://news.medxy.ai/ja/trabeculotomy-vs-combined-surgery-primary-congenital-glaucoma/Medxy AIja2026-11-12T02:25:28-08:00原発性先天緑内障における単純線維柱帯切開術と線維柱帯切開術・線維柱帯切除術併用術の3年間の治療成績の比較 https://news.medxy.ai/vi/trabeculotomy-vs-combined-surgery/Medxy AIvi2026-11-12T02:25:10-08:00Trabeculotomy đơn thuần so với phối hợp trabeculotomy-trabeculectomy ở glôcôm bẩm sinh nguyên phát có giãn giác mạc mức độ trung bình: Kết quả 3 năm https://news.medxy.ai/comparative-three-year-outcomes-of-trabeculotomy-versus-combined-trabeculotomy-trabeculectomy-in-primary-congenital-glaucoma-with-moderate-corneal-enlargement/Medxy AIen2026-11-12T02:24:54-08:00Comparative Three-Year Outcomes of Trabeculotomy Versus Combined Trabeculotomy-Trabeculectomy in Primary Congenital Glaucoma with Moderate Corneal Enlargement https://news.medxy.ai/zh/cholesteatoma-recurrence-risk-factors/Medxy AIzh2026-11-12T02:24:12-08:00胆脂瘤复发/残留：识别儿童高风险因素与疾病模式，优化管理策略 https://news.medxy.ai/ja/pediatric-cholesteatoma-recurrence/Medxy AIja2026-11-12T02:23:54-08:00小児で高い真珠腫再発リスク：病変進展と術式からみた最適管理の要点 https://news.medxy.ai/vi/pediatric-cholesteatoma-recurrence-2/Medxy AIvi2026-11-12T02:23:37-08:00Tái phát cholesteatoma ở trẻ em: nhận diện nguy cơ và mô hình bệnh để tối ưu hóa xử trí https://news.medxy.ai/cholesteatoma-recidivism-distinguishing-pediatric-risks-and-disease-patterns-for-optimized-management/Medxy AIen2026-11-12T02:23:20-08:00Cholesteatoma Recidivism: Distinguishing Pediatric Risks and Disease Patterns for Optimized Management https://news.medxy.ai/zh/neoadjuvant-pd1-melanoma/Medxy AIzh2026-11-12T02:22:38-08:00可切除Ⅲ期黑色素瘤中新辅助 PD-1 抑制剂疗效差异：淋巴结转移与移行转移的比较 https://news.medxy.ai/ja/pd1-neoadjuvant-melanoma/Medxy AIja2026-11-12T02:22:21-08:00切除可能なIII期メラノーマにおける術前PD-1阻害薬療法の有効性の差異：リンパ節転移と移行転移の比較 https://news.medxy.ai/vi/pd1-neoadjuvant-for-melanoma/Medxy AIvi2026-11-12T02:21:59-08:00Sự khác biệt về hiệu quả của các thuốc ức chế PD-1 trong điều trị tân bổ trợ đối với bệnh ung thư hắc tố giai đoạn III có thể phẫu thuật https://news.medxy.ai/distinct-clinical-outcomes-of-neoadjuvant-pd-1-inhibitors-in-resectable-stage-iii-melanoma-lymph-node-versus-in-transit-metastases/Medxy AIen2026-11-12T02:21:44-08:00Distinct Clinical Outcomes of Neoadjuvant PD-1 Inhibitors in Resectable Stage III Melanoma: Lymph Node Versus In-Transit Metastases https://news.medxy.ai/zh/baclofen-vaginal-suppositories/Medxy AIzh2026-11-12T02:21:05-08:00巴氯芬阴道栓剂治疗慢性盆腔痛：来自高质量随机对照试验的疗效证据及临床启示 https://news.medxy.ai/ja/baclofen-vaginal-suppositories-for-pelvic-pain/Medxy AIja2026-11-12T02:20:49-08:00慢性骨盤痛に対するバクロフェン膣坐剤：質の高いランダム化比較試験に基づく有効性のエビデンスと臨床的示唆 https://news.medxy.ai/vi/baclofen-vaginal-suppositories-pelvic-pain/Medxy AIvi2026-11-12T02:20:25-08:00Viên đặt âm đạo baclofen trong đau vùng chậu mạn tính: hiệu quả từ một thử nghiệm ngẫu nhiên có đối chứng quy mô lớn và ý nghĩa lâm sàng https://news.medxy.ai/vi/modern-hepatitis-d-care/Medxy AIvi2026-11-12T02:20:13-08:00AASLD EXPO: Hiện đại hóa tiếp cận viêm gan D — Ai cần xét nghiệm, ai cần điều trị và theo dõi như thế nào https://news.medxy.ai/baclofen-vaginal-suppositories-in-chronic-pelvic-pain-efficacy-from-a-robust-randomized-controlled-trial-and-clinical-implications/Medxy AIen2026-11-12T02:20:08-08:00Baclofen Vaginal Suppositories in Chronic Pelvic Pain: Efficacy from a Robust Randomized Controlled Trial and Clinical Implications https://news.medxy.ai/zh/hepatitis-delta-care/Medxy AIzh2026-11-12T02:19:47-08:00AASLD EXPO：重塑丁型肝炎诊疗路径——谁需要检测、谁应治疗、如何随访监测 https://news.medxy.ai/ja/hepatitis-delta-management/Medxy AIja2026-11-12T02:19:43-08:00AASLD EXPO：肝炎デルタへの最新アプローチ——誰を検査し、誰を治療し、どのようにモニタリングするか https://news.medxy.ai/hepatitis-d-management/Medxy AIen2026-11-12T02:19:23-08:00AASLD EXPO: Modernizing the Approach to Hepatitis D — Who to Test, Who to Treat, and How to Monitor https://news.medxy.ai/zh/late-nc-cognitive-decline/Medxy AIzh2026-11-12T02:18:24-08:00LATE-NC与认知下降：来自巴西多样化尸检队列的研究启示 https://news.medxy.ai/ja/late-nc-cognitive-decline-brazil-autopsy-cohort/Medxy AIja2026-11-12T02:18:05-08:00LATE-NCと認知機能低下：多様なブラジル剖検コホートから得られた知見 https://news.medxy.ai/vi/late-nc-cognitive-decline-brazil/Medxy AIvi2026-11-12T02:17:50-08:00LATE-NC và sự suy giảm nhận thức: Những hiểu biết từ một nhóm đối tượng đa dạng trong nghiên cứu khám nghiệm tử thi tại Brazil https://news.medxy.ai/late-nc-and-cognitive-decline-insights-from-a-diverse-brazilian-autopsy-cohort/Medxy AIen2026-11-12T02:17:34-08:00LATE-NC and Cognitive Decline: Insights from a Diverse Brazilian Autopsy Cohort https://news.medxy.ai/zh/slc2a2-glimepiride-efficacy/Medxy AIzh2026-11-12T02:16:54-08:00SLC2A2遗传变异如何影响格列美脲疗效：来自 GRADE 试验的血糖反应新发现 https://news.medxy.ai/ja/slc2a2-genetic-variants/Medxy AIja2026-11-12T02:16:38-08:00グリメピリドの血糖応答を左右するSLC2A2遺伝変異：GRADE試験から見えた薬効差の背景 https://news.medxy.ai/vi/slc2a2-glimepiride-response/Medxy AIvi2026-11-12T02:16:28-08:00Biến thể SLC2A2 và đáp ứng với glimepiride: gợi ý di truyền từ thử nghiệm GRADE https://news.medxy.ai/genetic-insights-into-glycemic-response-role-of-slc2a2-variants-in-sulfonylurea-efficacy-from-the-grade-trial/Medxy AIen2026-11-12T02:16:14-08:00Genetic Insights into Glycemic Response: Role of SLC2A2 Variants in Sulfonylurea Efficacy from the GRADE Trial https://news.medxy.ai/zh/transseptal-tmvr-outcomes/Medxy AIzh2026-11-12T02:15:36-08:00经皮经房间隔TMVR的持久疗效与安全性：ENCIRCLE试验2年结果 https://news.medxy.ai/ja/two-year-tmvr-results/Medxy AIja2026-11-12T02:15:15-08:00経皮的経中隔TMVRの持続的有効性と安全性：ENCIRCLE試験2年成績 https://news.medxy.ai/vi/transcatheter-tmvr-outcomes/Medxy AIvi2026-11-12T02:14:56-08:00TMVR xuyên vách liên nhĩ bằng đường qua da: Hiệu quả và an toàn bền vững sau 2 năm từ thử nghiệm ENCIRCLE https://news.medxy.ai/durable-efficacy-and-safety-of-percutaneous-transseptal-tmvr-two-year-outcomes-from-the-encircle-trial/Medxy AIen2026-11-12T02:14:38-08:00Durable Efficacy and Safety of Percutaneous Transseptal TMVR: Two-Year Outcomes from the ENCIRCLE Trial https://news.medxy.ai/zh/oncology-trainee-diversity-trends/Medxy AIzh2026-11-12T02:13:54-08:00肿瘤学多元化进展：2011—2025年培训人员种族与族裔代表性趋势 https://news.medxy.ai/ja/diversity-in-oncology-training/Medxy AIja2026-11-12T02:13:33-08:00腫瘍学における多様性の前進：2011年から2025年にかけての研修中医師における人種・民族構成の動向 https://news.medxy.ai/vi/racial-diversity-oncology/Medxy AIvi2026-11-12T02:13:14-08:00Tăng cường đa dạng trong ung bướu: xu hướng đại diện chủng tộc và sắc tộc ở học viên giai đoạn 2011–2025 https://news.medxy.ai/advancing-diversity-in-oncology-trends-in-racial-and-ethnic-representation-among-trainees-from-2011-to-2025/Medxy AIen2026-11-12T02:13:00-08:00Advancing Diversity in Oncology: Trends in Racial and Ethnic Representation Among Trainees from 2011 to 2025 https://news.medxy.ai/zh/adipose-stromal-therapy-knee-osteoarthritis/Medxy AIzh2026-11-12T02:12:23-08:00单次自体基质血管组分注射治疗中重度膝骨关节炎的疗效：来自多中心随机对照试验的启示 https://news.medxy.ai/ja/adipose-stromal-therapy-for-knee-osteoarthritis/Medxy AIja2026-11-12T02:12:08-08:00中等度から重度の膝変形性関節症に対する自己由来基質血管画分（SVF）の単回注射療法の有効性：多施設共同ランダム化比較試験からの知見 https://news.medxy.ai/vi/adipose-stromal-cell-therapy-knee-osteoarthritis/Medxy AIvi2026-11-12T02:11:47-08:00Hiệu quả của một lần tiêm phân đoạn mạch máu mô đệm tự thân (autologous stromal vascular fraction) trong điều trị thoái hóa khớp gối mức độ trung bình đến nặng https://news.medxy.ai/efficacy-of-a-single-autologous-stromal-vascular-fraction-injection-for-moderate-to-severe-knee-osteoarthritis-insights-from-a-multicenter-randomized-controlled-trial/Medxy AIen2026-11-12T02:11:31-08:00Efficacy of a Single Autologous Stromal Vascular Fraction Injection for Moderate-to-Severe Knee Osteoarthritis: Insights from a Multicenter Randomized Controlled Trial https://news.medxy.ai/zh/pace-impact-young-disabled-adults/Medxy AIzh2026-11-12T02:10:48-08:00PACE对较年轻残障成年人影响如何？——健康、参与度与医疗利用结局分析 https://news.medxy.ai/ja/pace-impact-on-young-disabled-adults/Medxy AIja2026-11-12T02:10:33-08:00PACEは若年層の障害を持つ成人にどのような影響を及ぼすか？――健康、社会参加、および医療利用に関するアウトカム分析 https://news.medxy.ai/vi/pace-impact-young-adults-disabilities/Medxy AIvi2026-11-12T02:10:16-08:00Đánh giá tác động của PACE ở người trưởng thành trẻ sống chung với khuyết tật: kết cục về sức khỏe, sự gắn kết và sử dụng dịch vụ y tế https://news.medxy.ai/evaluating-the-impact-of-pace-on-younger-adults-with-disabilities-health-engagement-and-healthcare-utilization-outcomes/Medxy AIen2026-11-12T02:10:00-08:00Evaluating the Impact of PACE on Younger Adults with Disabilities: Health, Engagement, and Healthcare Utilization Outcomes https://news.medxy.ai/zh/silver-fluoride-vs-restorations/Medxy AIzh2026-11-12T02:09:22-08:00老年人龋病管理：银氨氟化物与无创修复治疗孰优？——来自整群随机试验的启示 https://news.medxy.ai/ja/silver-diamine-fluoride-restorative-care/Medxy AIja2026-11-12T02:09:04-08:00高齢者のう蝕管理における銀ジアミンフッ化物と非侵襲的修復治療：クラスターランダム化試験からの知見 https://news.medxy.ai/vi/silver-diamine-fluoride-vs-atraumatic-restorative-treatment/Medxy AIvi2026-11-12T02:08:41-08:00Fluor bạc diamin so với điều trị phục hồi không gây sang chấn trong kiểm soát sâu răng ở người cao tuổi: góc nhìn từ một thử nghiệm ngẫu nhiên theo cụm https://news.medxy.ai/silver-diamine-fluoride-vs-atraumatic-restorations-for-caries-management-in-older-adults-insights-from-a-cluster-randomized-trial/Medxy AIen2026-11-12T02:08:26-08:00Silver Diamine Fluoride vs Atraumatic Restorations for Caries Management in Older Adults: Insights from a Cluster-Randomized Trial https://news.medxy.ai/zh/retatrutide-obesity-treatment/Medxy AIzh2026-11-12T02:07:50-08:00Retatrutide：用于肥胖及相关合并症管理的有前景三重激素受体激动剂 https://news.medxy.ai/ja/retatrutide-treatment-obesity/Medxy AIja2026-11-12T02:07:33-08:00レタトルチド：肥満および関連する合併症の管理に向けた、有望なトリプルホルモン受容体作動薬 https://news.medxy.ai/vi/retatrutide-obesity-treatment-2/Medxy AIvi2026-11-12T02:07:16-08:00Retatrutide: Chất chủ vận ba hormon đầy hứa hẹn trong điều trị béo phì và các bệnh đồng mắc liên quan https://news.medxy.ai/retatrutide-a-promising-triple-hormone-receptor-agonist-for-obesity-management-and-related-comorbidities/Medxy AIen2026-11-12T02:06:56-08:00Retatrutide: A Promising Triple Hormone Receptor Agonist for Obesity Management and Related Comorbidities